This Biotech Is Aiming To Help Overcome Public-Speaking Fears [Investor's Business Daily]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Investors Business Daily
Related news Biohaven Pharmaceutical ( BHVN ) stock jumped 6% on Thursday after its anti-anxiety treatment showed promise in patients tasked with public speaking. The drug, known by the test name as BHV-0223, improved anxiety compared with a placebo in patients previously diagnosed with social anxiety disorder and public speaking anxiety. Biohaven is working with the Yale University School of Medicine to develop the drug. Based on the results, Biohaven said it will also work on developing a treatment for general anxiety disorder. The firm is looking to target a chemical called glutamate and a receptor. It has several potential drugs for neurologic and neuropsychiatric disorders. The findings "suggest the therapeutic potential of glutamate modulation in the treatment of anxiety disorders," Michael Bloch, a Yale University School of Medicine spokesperson, said in a written statement. Researchers studied 21 people with diagnosed anxiety disorders. They tasked participants with performin
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Independent Director of Biohaven John Childs Buys 3.2% More Shares [Yahoo! Finance]Yahoo! Finance
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at UBS Group AG from $59.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesPR Newswire
- Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
BHVN
Earnings
- 11/14/23 - Miss
BHVN
Sec Filings
- 4/25/24 - Form 4
- 4/23/24 - Form 4
- 4/23/24 - Form 4
- BHVN's page on the SEC website